Ifosfamide
. Draft fact sheet, awaiting Henry's approval. Items marked [check] must be verified before publishing.
← All drugs · Search the portal
Facts
| Topic | Fact | Source (access date) |
|---|---|---|
| First US approval record | Ifex (NDA 019763, Baxter): Drugs@FDA earliest submission date 14 Aug 1987, about 39 years | Drugs@FDA via openFDA, https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA019763 (accessed 4 Nov 2026) |
| Mechanism | Alkylating agent (oxazaphosphorine); activated in the liver, then damages DNA | eMC SmPC https://www.medicines.org.uk/emc/product/1834/smpc (accessed 4 Nov 2026) |
| Use in osteosarcoma | Mainly relapse or tumours growing on MAP/AP; UK guideline says ifosfamide/etoposide gives the highest response rates at relapse. In MAPIE (EURAMOS-1) for poor responders: no benefit. In France historically first line. Listed second line in NCCN and CSCO | UK bone sarcoma guidelines 2024, https://pmc.ncbi.nlm.nih.gov/articles/PMC11723950/ (accessed 3 Nov 2026); NCCN via secondary source https://www.cancertherapyadvisor.com/ddi/bone-cancer-treatment-pharmacologic-management/ (accessed 31 Oct 2026; primary NCCN not opened); CSCO guideline and 2026 Chinese paediatric guideline, via /workspace/osteo-videos/level2/treatment_by_country.md (accessed 31 Oct 2026) |
| Combined with | Etoposide (IE); MAP (MAPIE); doxorubicin and cisplatin (API-AI); mesna to protect the bladder | EURAMOS-1 MAPIE vs MAP, Marina et al., Lancet Oncol 2016, doi:10.1016/S1470-2045(16)30214-5 (PMID 27569442), accessed 3 Nov 2026; treatment_by_country.md |
| Results | EURAMOS-1 poor responders (618 randomised): MAPIE v MAP event-free survival hazard ratio 0.98, more toxicity | EURAMOS-1 MAPIE vs MAP, Marina et al., Lancet Oncol 2016, doi:10.1016/S1470-2045(16)30214-5 (PMID 27569442), accessed 3 Nov 2026 |
| Side effects | Haemorrhagic cystitis (mesna used), kidney damage (very common), encephalopathy, low blood counts, infertility, nausea and vomiting, hair loss | eMC SmPC https://www.medicines.org.uk/emc/product/1834/smpc (accessed 4 Nov 2026) |
| Owner and generic status | US Ifex (Baxter); UK and Ireland licences held by Baxter; now generic | Drugs@FDA NDA019763 (accessed 4 Nov 2026); eMC SmPC https://www.medicines.org.uk/emc/product/1834/smpc (accessed 4 Nov 2026); HPRA SmPC https://assets.hpra.ie/products/Human/15731/Licence_PA2299-028-001_11092023124600.pdf (accessed 4 Nov 2026) |
| Regulatory | UK: Baxter PL 00116/0392 (first 15 Dec 2003), general licence for malignant disease; section 5.1 lists osteosarcoma among paediatric tumours studied. EU (Ireland): Mitoxana, Baxter PA2299/028/001, same wording. US: third-line germ cell testicular cancer. China: domestic approvals e.g. H20093071. In CSCO second line | eMC SmPC https://www.medicines.org.uk/emc/product/1834/smpc (accessed 4 Nov 2026); HPRA SmPC https://assets.hpra.ie/products/Human/15731/Licence_PA2299-028-001_11092023124600.pdf (accessed 4 Nov 2026); NMPA H20093071 via https://www.yaozs.com/z24590/ (accessed 4 Nov 2026) (secondary mirror) |
Hypotheses and open points (not established fact)
- Higher-dose ifosfamide gives better responses than standard dose in relapse: reported in single-arm series, not randomised.